Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.

DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Primary tabs

Lees, Kennedy R Bluhmki, Erich von Kummer, Rüdiger Brott, Thomas G Toni, Danilo Laloux, Patrice [UCL] et al.[show all]

None.

Document type	Article de périodique (Journal article) – Article de recherche
Access type	Accès restreint
Publication date	2010
Language	Anglais
Journal information	"The Lancet" - Vol. 375, no.9727, p. 1695-703 (2010)
Peer reviewed	yes
Publisher	TheLancet Publishing Group ((United Kingdom) London)
issn	0140-6736
e-issn	1474-547X
Publication status	Publié
Affiliations	UCL - SSS/IONS - Institute of NeuroScience UCL - (MGD) Service de neurologie UCL - SSS/IONS/NEUR - Clinical Neuroscience
MESH Subject	Fibrinolytic Agents ; Tissue Plasminogen Activator ; Treatment Outcome ; Humans ; Infusions, Intravenous ; Injections, Intravenous ; Intracranial Hemorrhages ; Randomized Controlled Trials as Topic ; Recombinant Proteins ; Stroke ; Time Factors
Links	http://hdl.handle.net/2078.1/132708[Handle] https://doi.org/10.1016/S0140-6736(10)60491-6[DOI] http://www.ncbi.nlm.nih.gov/pubmed/20472172[Pubmed]

Bibliographic reference	Lees, Kennedy R ; Bluhmki, Erich ; von Kummer, Rüdiger ; Brott, Thomas G ; Toni, Danilo ; et. al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.. In: The Lancet, Vol. 375, no.9727, p. 1695-703 (2010)
Permanent URL	http://hdl.handle.net/2078.1/132708